Unexpected outbreak of Epstein-Barr virus post-transplantation lymphoproliferative disorder after hematopoietic stem cell transplantation conditioning with thymoglobulin.

[1]  A. Bacigalupo.  Antilymphocyte/thymocyte globulin for graft versus host disease prophylaxis: efficacy and side effects , 2005, Bone Marrow Transplantation.

[2]  P. Ljungman,et al.  Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation , 2014, Haematologica.

[3]  J. Preiksaitis,et al.  Post-transplant lymphoproliferative disorder. , 1995, Infectious disease clinics of North America.

[4]  Allen R Nissenson,et al.  Pure red-cell aplasia and epoetin therapy. , 2004, The New England journal of medicine.

[5]  M. Mohty,et al.  Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond , 2007, Leukemia.

[6]  Jian Cheng,et al.  Quality of life of patients after allogeneic hematopoietic stem cell transplantation with antihuman thymocyte globulin. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  E. Jaffe,et al.  Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. , 2009, Blood.

[8]  F. Appelbaum,et al.  Anti-T cell antibodies as part of the preparative regimen in hematopoietic cell transplantation--a debate. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[9]  H. Einsele,et al.  EBV-induced post transplant lymphoproliferative disorders: a persisting challenge in allogeneic hematopoetic SCT , 2014, Bone Marrow Transplantation.